Zum Inhalt springen
| Eingeschlossene Patienten: 20.371 (Stand 1. April 2021) | |
| Amgevita® (Adalimumab) | 110 |
| Benepali® (Etanercept) | 775 |
| Cimzia® (Certolizumab) | 949 |
| Enbrel® (Etanercept) | 2866 |
| Erelzi® (Etanercept) | 341 |
| Flixabi® (Infliximab) | 9 |
| Hulio® (Adalimumab) | 67 |
| Humira® (Adalimumab) | 2903 |
| Hyrimoz® (Adalimumab) | 87 |
| Idacio® (Adalimumab) | 25 |
| Imraldi® (Adalimumab) | 112 |
| Inflectra™ (Infliximab) | 16 |
| Jyseleca® (Filgotinib) | 10 |
| Kevzara® (Sarilumab) | 156 |
| Kineret® (Anakinra) | 89 |
| MabThera® (Rituximab) | 1458 |
| Nepexto® (Etanercept) | 11 |
| Olumiant® (Baricitinib) | 437 |
| Orencia® (Abatacept) | 865 |
| Remicade® (Infliximab) | 762 |
| Remsima® (Infliximab) | 11 |
| Rinvoq® (Upadacitinib) | 139 |
| Rixathon® (Rituximab) | 16 |
| RoActemra® (Tocilizumab) | 1331 |
| Ruxience® (Rituximab) | 1 |
| Simponi® (Golimumab) | 447 |
| Xeljanz® (Tofacitinib) | 350 |
| Zessly® (Infliximab) | 2 |
| Kontrollen | 6026 |
